Yogita Bahl
About Yogita Bahl
Yogita Bahl is the Senior Director/Team Lead RegCMC Cell Therapy at Bristol Myers Squibb, with over 20 years of experience in the biotech sector, specializing in regulatory CMC strategy, drug development, and commercialization.
Title
Yogita Bahl holds the title of Senior Director/Team Lead RegCMC Cell Therapy at Bristol Myers Squibb in Summit, New Jersey, United States.
Professional Background
Yogita Bahl has an extensive career in the biotech and pharmaceutical industries, beginning with her role as a Senior Scientist I at Cardinal Health in 2002. Over the years, she advanced through roles at Wyeth Vaccines, Amgen Inc., and Merck, concentrating on areas such as regulatory affairs, product commercialization, and development of sterile liquid products. She served at Daiichi Sankyo, Inc. as Director, Team Lead RegCMC Biologics from 2019 to 2022. Prior to her current role, she worked at Novartis as Director Regulatory CMC Biologics from 2017 to 2019.
Education and Expertise
Yogita Bahl earned her Ph.D. in Pharmaceutical Sciences from the University of Tennessee-Health Science Center College of Medicine in 2002. She also holds a Bachelor of Science in Pharmacy from the University of Mumbai, completed in 1996. She specializes in monoclonal antibodies, biosimilars, vaccines, and antibody-drug conjugates (ADC). Bahl is an expert in fill/finish scale-up and technology transfer for vials, pre-filled syringes, and cartridges.
Professional Achievements
Throughout her career, Yogita Bahl has been involved in new technology evaluation and CMC regulatory filing. She has a proven track record of leading cross-functional projects to completion within aggressive timelines, emphasizing scientific integrity and quality. Her expertise extends to liquid protein formulation development, stability evaluation, lyophilization, and medical devices.
Industry Leadership
In addition to her roles in various companies, Yogita Bahl serves as the Co-Chair of the Regulatory Affairs Professionals Society (RAPS) NY/NJ Chapter. This role highlights her leadership within the industry and her commitment to advancing regulatory affairs practices.